📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
386 announcements match the current filters (relevance ≥ 5).
Sai Parenterals Q4 PAT Surges 736% to ₹13.25 Cr; FY27 Revenue Target Set at ₹750 Cr
Sai Parenterals reported an exceptional Q4 FY26 with PAT surging 736% YoY to ₹13.25 crore, driven by the successful integration of Noumed (Australia) and a 250% jump in CDMO revenues. Full-year FY26 revenue grew 140% to ₹380.99 crore, reflecting the impact of strategic acquisitions and export growth. The company successfully completed its IPO in March 2026, raising ₹285 crore to fund a massive ₹440 crore capex program. Management has issued aggressive guidance for FY27, targeting ₹750 crore in revenue and an improved EBITDA margin of 17%.
Key Highlights
Q4 FY26 revenue grew 166.65% YoY to ₹197.93 Cr, while PAT increased 736.04% to ₹13.25 Cr.
FY26 consolidated revenue reached ₹380.99 Cr (+140.37% YoY) following the acquisition of Noumed Australia.
Management targets FY27 revenue of ₹750 Cr and EBITDA margins of 17%, nearly doubling current revenue levels.
Ongoing capex of ₹440 Cr includes a new R&D center in India and Australia's largest modern pharmaceutical plant.
CDMO revenues surged by over 250% YoY, supported by 88 new product dossiers added in FY26 and 67 more in the pipeline.
👀 What to Watch
Investors should focus on the company's ability to execute its ₹440 crore capex and achieve the ambitious ₹750 crore revenue target for FY27. The stock remains a high-growth play in the CDMO and injectable space following its recent listing and successful Australian integration.
Paramount Communications FY26 Revenue Up 23% to ₹19,122 Mn; Q4 PAT Recovers by 9.5%
Paramount Communications reported a 22.8% YoY growth in FY26 revenue to ₹19,122 Mn, though full-year PAT declined 30.5% to ₹602 Mn due to US tariff disruptions. However, Q4 FY26 showed a strong recovery with PAT rising 9.5% YoY to ₹205 Mn as the company successfully pivoted to the domestic market. The domestic order book grew significantly by 55% YoY to ₹5,078 Mn, helping offset a 77% decline in export orders. The company is also progressing with a ₹300 Cr Greenfield expansion in Madhya Pradesh to enter the high-margin EHV cable segment by FY28.
Key Highlights
FY26 Revenue grew 22.8% YoY to ₹19,122 Mn, while full-year EBITDA margin compressed to 6.0% from 8.5%.
Q4 FY26 EBITDA margin recovered to 6.7% from 4.3% in Q3 FY26, signaling a turnaround from export tariff impacts.
Domestic order book reached a record ₹5,078 Mn (+55% YoY), driven by a 66% surge in power cable demand.
Greenfield project in Narmadapuram involves ₹300 Cr investment for EHV cables with partial commissioning in Q1 FY28.
Metal throughput increased 12% YoY to 29,664 MTPA, maintaining a strong 3-year CAGR of approximately 45%.
👀 What to Watch
Investors should monitor the stabilization of export margins and the execution timeline of the Narmadapuram EHV project. While domestic growth is robust, the company's ability to navigate global trade volatility remains a key factor for long-term profitability.
Sai Parenterals Reports Zero Deviation in Utilization of ₹2,850 Million IPO Proceeds
Sai Parenterals Limited has submitted its statement of deviation for the quarter and year ended March 31, 2026, confirming that IPO funds are being handled as per the offer document. The company raised ₹2,850 million through its Initial Public Offer in late March 2026. As of the reporting date, no funds have been diverted from their original objects, which include significant allocations for capacity expansion and debt repayment. The monitoring agency, India Ratings & Research, and the company's Audit Committee have reviewed and confirmed the status.
Key Highlights
Successfully raised ₹2,850 million through an IPO conducted between March 24 and March 27, 2026.
Confirmed zero deviation or variation in the utilization of proceeds for the period ending March 31, 2026.
Major allocations include ₹1,107.95 million for capacity expansion and ₹356.41 million for loan repayments related to the acquisition of Noumed Pharmaceuticals (Australia).
Allocated ₹180.23 million for the establishment of a new R&D Centre and ₹330 million for working capital requirements.
India Ratings & Research Private Limited is acting as the monitoring agency for the fund utilization.
👀 What to Watch
Investors should track subsequent quarterly filings to ensure the ₹2,850 million is deployed timely into the high-growth capacity expansion and R&D projects as promised.
Sai Parenterals Reports Q3 FY26 Consolidated PAT of ₹33.37 Million Post-IPO
Sai Parenterals Limited has released its first set of financial results post-listing for the quarter and nine months ended December 31, 2025. On a consolidated basis, the company reported a revenue of ₹892.11 million for the quarter, though it faced a loss before tax of ₹16.25 million, which turned into a PAT of ₹33.37 million due to deferred tax credits. The standalone performance remained profitable with a nine-month PAT of ₹68.28 million. A significant development is the completed acquisition of a 74.64% stake in UK-based Noumed Life Sciences for AUD 22 million, which is now reflected in the consolidated figures.
Key Highlights
Consolidated Revenue from Operations for Q3 FY26 stood at ₹892.11 million.
Consolidated Profit After Tax (PAT) for the quarter was ₹33.37 million, supported by a ₹55.57 million deferred tax credit.
Standalone Nine-Month revenue reached ₹1,054.59 million with a PAT of ₹68.28 million.
Completed acquisition of 74.64% stake in Noumed Life Sciences Limited (UK) for an aggregate consideration of AUD 22 million.
The company reported an unmodified audit opinion for the financial year ended March 31, 2026.
👀 What to Watch
Investors should closely monitor the operational integration of the UK-based Noumed Life Sciences, as the consolidated entity is currently reporting losses at the pre-tax level despite high revenue scaling. The stock's performance will likely depend on the company's ability to turn the consolidated operations profitable without relying on tax adjustments.
Sai Parenterals Q3 FY26 Consolidated Revenue at ₹892.1M; Completes Noumed UK Acquisition
Sai Parenterals reported a consolidated revenue of ₹892.11 million for the quarter ended December 31, 2025, with a net profit of ₹33.37 million. The standalone performance for the same quarter showed a revenue of ₹384.79 million and a profit of ₹3.63 million. A major strategic milestone was the completion of a 74.64% stake acquisition in UK-based Noumed Life Sciences Limited for AUD 22 million. As the company was recently listed, year-on-year comparative figures for the previous financial year are not available.
Key Highlights
Consolidated revenue for Q3 FY26 reached ₹892.11 million with a PAT of ₹33.37 million.
Standalone 9-month revenue stood at ₹1,054.59 million with a PAT of ₹68.28 million.
Completed acquisition of 74.64% stake in Noumed Life Sciences (UK) for a total consideration of AUD 22 million.
Consolidated 9-month revenue reported at ₹1,530.71 million, indicating strong contribution from international subsidiaries.
Statutory auditors issued an unmodified opinion on the audited financial results for the year ended March 31, 2026.
👀 What to Watch
Investors should monitor the integration of the Noumed UK acquisition and its impact on consolidated margins in future quarters. As a newly listed entity, focus on the company's ability to maintain revenue growth in the branded generic and CDMO segments.
Paramount Communications FY26 Revenue Rises 23% to ₹1,912 Cr; Annual PBT Declines to ₹81 Cr
Paramount Communications reported a strong 23% year-on-year growth in annual revenue, reaching ₹1,912.16 crore for FY26. However, the company's full-year Profit Before Tax (PBT) saw a decline to ₹81.31 crore from ₹110.60 crore in the previous year, impacted by rising finance and operational costs. Quarterly performance showed resilience with Q4 FY26 revenue at ₹573.30 crore, up from ₹504.85 crore YoY. The board also approved the re-appointment of internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Annual Revenue from operations grew 22.8% YoY to ₹1,912.16 crore in FY26.
Full-year Profit Before Tax (PBT) decreased by 26.5% to ₹81.31 crore compared to ₹110.60 crore in FY25.
Finance costs nearly doubled during the year, rising from ₹10.87 crore to ₹21.03 crore.
Q4 FY26 Revenue showed a 13.6% YoY increase, reaching ₹573.30 crore.
Other Income for the full year jumped significantly to ₹51.77 crore from ₹12.83 crore in the previous fiscal.
👀 What to Watch
Investors should monitor the company's ability to manage rising finance costs and operating expenses, which are currently offsetting healthy revenue growth. While the top-line expansion is positive, the compression in annual profit margins warrants a cautious approach.
Paradeep Phosphates Wins Tax Dispute: ₹20.61 Cr Demand Quashed and ₹20.57 Cr Refund Granted
Paradeep Phosphates Limited has received a favorable rectification order from the Income Tax Department for Assessment Year 2020-21. The Assistant Commissioner of Income Tax has quashed a previously raised tax demand of ₹20.61 crore and granted a refund of ₹20.57 crore to the company. This resolution follows a dispute regarding the adjustment of carry-forward losses and MAT credits. The outcome is a significant positive for the company's cash flow and removes a material legal uncertainty.
Key Highlights
Income Tax demand of ₹20.61 crore for AY 2020-21 has been officially quashed.
The company has been granted a tax refund amounting to ₹20.57 crore.
The order was passed under Section 154 of the Income-tax Act, 1961, by the ACIT, Bhubaneswar.
The dispute involved adjustments related to carry-forward losses and MAT credits from earlier years.
👀 What to Watch
Investors should view this as a positive development that strengthens the balance sheet and improves liquidity. No further action is required as the litigation has reached a favorable conclusion.
Park Medi World Incorporates Step-Down Subsidiary Healplus Medical Services for Expansion
Park Medi World Limited has announced the incorporation of a new step-down subsidiary, Healplus Medical Services Private Limited, through its 81.81% owned subsidiary Park Medicenters and Institutions Private Limited. The new entity is a wholly-owned subsidiary of Park Medicenters and was incorporated on May 20, 2026, with an initial capital infusion of INR 0.01 crore. This new unit will focus on the retail and wholesale distribution of pharmaceuticals, medical goods, and healthcare products. The move is strategically aimed at diversifying the company's current healthcare operations into the pharmacy and wellness retail segments.
Key Highlights
Incorporated 'Healplus Medical Services Private Limited' as a wholly-owned step-down subsidiary on May 20, 2026
Parent company Park Medi World holds 81.81% equity in the immediate subsidiary, Park Medicenters
Initial cost of acquisition and capital infusion is set at INR 0.01 crore in cash
Business focus includes retail, wholesale, and distribution of pharmaceuticals, surgical goods, and wellness products
Strategic objective is to diversify and expand existing healthcare business operations through new outlets and pharmacies
👀 What to Watch
Investors should monitor the scaling of this new retail pharmacy and distribution arm as it represents a vertical integration strategy. While the initial investment is small, successful execution could provide a steady secondary revenue stream alongside hospital operations.
SPARC Partner Receives US FDA CRL for PDP-716 NDA Over Manufacturing Issues
Sun Pharma Advanced Research Company (SPARC) announced that its licensing partner, Ocuvex Therapeutics Inc., has received a Complete Response Letter (CRL) from the US FDA for the PDP-716 New Drug Application. The CRL was issued specifically due to inspection findings at the finished product manufacturing facility, rather than clinical or safety concerns. While the FDA did not raise any other issues with the NDA, this development delays the potential commercialization and revenue generation from this product. Investors should note that the path to approval now depends on the successful remediation of the manufacturing facility's deficiencies.
Key Highlights
US FDA issued a Complete Response Letter (CRL) for the PDP-716 New Drug Application (NDA).
The CRL is attributed to inspection findings at the finished product manufacturing facility.
FDA confirmed no other issues or deficiencies were raised regarding the PDP-716 NDA itself.
The licensing partner involved in the US market for this drug is Ocuvex Therapeutics Inc.
Approval and subsequent launch of PDP-716 will be delayed until manufacturing issues are resolved.
👀 What to Watch
Investors should monitor for updates regarding the remediation of the manufacturing facility and the timeline for a potential resubmission to the FDA. The stock may face short-term pressure due to the delay in expected milestone or royalty income.
SPARC Allots 3.85 Crore Warrants to Raise Up to ₹600 Crore on Preferential Basis
Sun Pharma Advanced Research Company Limited (SPARC) has approved the allotment of 3,85,10,000 warrants to Shanghvi Finance Private Limited on a preferential basis. The warrants are issued at a price of INR 155.80 each, bringing the total potential fundraise to approximately INR 600 crore. The company has received an upfront payment of INR 149.99 crore, which constitutes 25% of the total warrant issue price. Each warrant is convertible into one equity share of face value INR 1, which will lead to equity dilution upon conversion.
Key Highlights
Allotment of 3,85,10,000 warrants to promoter group entity Shanghvi Finance Private Limited.
Warrants issued at a price of INR 155.80 per warrant, totaling a potential fundraise of ~INR 600 crore.
Upfront receipt of INR 149.99 crore, representing 25% of the total warrant issue price.
Each warrant is convertible into one fully paid-up equity share of face value INR 1 within regulatory timelines.
👀 What to Watch
Investors should view this capital infusion positively as it provides SPARC with essential funding for its research and development pipeline. However, shareholders should keep in mind the impending equity dilution when these warrants are converted into shares.
SPARC Reports Massive Q4 Profit of ₹1,761 Cr Driven by ₹1,840 Cr PRV Monetization
SPARC reported a massive turnaround in Q4 FY26 with a net profit of ₹1,760.7 crore, compared to a loss of ₹61 crore in the same period last year. This surge is primarily attributed to the recognition of ₹1,840 crore in revenue from a Priority Review Voucher (PRV) granted by the USFDA for Sezaby®, which was sold for $195 million. For the full financial year 2026, the company posted a profit of ₹1,552 crore against a loss of ₹345 crore in FY25. This one-time windfall significantly boosts the company's cash reserves and equity position.
Key Highlights
Net Profit of ₹1,760.7 crore in Q4 FY26 vs a loss of ₹61 crore in Q4 FY25
Recognized ₹1,840 crore in other operating revenue from the sale of a USFDA Priority Review Voucher
Full-year FY26 profit stands at ₹1,552 crore compared to a loss of ₹345 crore in FY25
Total income for the quarter surged to ₹1,855 crore from just ₹27 crore YoY
Earnings Per Share (EPS) for the quarter jumped to ₹54.26 from a negative ₹1.88 YoY
👀 What to Watch
Investors should recognize this as a significant one-time windfall that provides SPARC with substantial capital to fund its expensive R&D pipeline. While the core research business remains loss-making, the strengthened balance sheet reduces immediate dilution risks.
BIL Vyapar Limited Schedules 11th Committee of Creditors Meeting for May 19, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 11th meeting of its Committee of Creditors (CoC) scheduled for May 19, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in the ongoing legal efforts to resolve the company's debt and determine its future viability. Equity shareholders should remain cautious as insolvency proceedings often result in significant restructuring or liquidation.
Key Highlights
11th meeting of the Committee of Creditors (CoC) to be held on May 19, 2026.
Company is currently under the Corporate Insolvency Resolution Process (CIRP).
Disclosure made pursuant to Regulation 30 and Para 16(g) of SEBI LODR Regulations.
BIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR).
👀 What to Watch
Investors should exercise extreme caution as equity value is typically at high risk during insolvency proceedings. Monitor for updates regarding any approved resolution plans or liquidation orders.
Paramount Communications to Raise ₹92.4 Cr via Preferential Issue; EGM on June 06
Paramount Communications (PARACABLES) has called an Extraordinary General Meeting (EGM) on June 06, 2026, to approve a significant fundraise. The company proposes to issue approximately 2.2 crore equity shares at ₹42 per share, totaling ₹92.40 crores, alongside convertible warrants. Marquee institutional investors including Abakkus Diversified Alpha Fund (Sunil Singhania's fund) and Subhkam Ventures are the primary participants in this preferential allotment.
Key Highlights
Issuance of up to 2,19,97,664 equity shares at a price of ₹42 per share (including ₹40 premium).
Total equity fundraise estimated at ₹92.40 crores from non-promoter investors.
Abakkus Diversified Alpha Fund and its second series are the lead investors, contributing ₹50 crores.
Other notable participants include Subhkam Ventures (₹10 Cr) and Singularity Equity Fund II (₹5 Cr).
The relevant date for floor price calculation was fixed as May 07, 2026.
👀 What to Watch
The participation of marquee investors like Abakkus suggests strong institutional confidence in the company's growth trajectory. Investors should view this as a positive development for long-term capital structure, while keeping an eye on the dilution impact.
Park Medi World FY26 PAT Jumps 27% to ₹274 Cr; Bed Capacity to Reach 5,460 by 2028
Park Medi World reported its strongest financial year in FY26, with revenue growing 21% to ₹1,679 crores and PAT rising 27% to ₹274 crores. The company significantly expanded its footprint by adding 610 beds, entering new markets in Uttar Pradesh and Punjab, reaching a total capacity of 3,610 beds by year-end. Operational efficiency improved with occupancy rising to 64.1% and ARPOB increasing to ₹28,000. The balance sheet was substantially deleveraged, with gross debt falling from ₹450 crores to just ₹28 crores, providing a strong foundation for future growth.
Key Highlights
Annual revenue grew 21% YoY to ₹1,679 crores with a healthy EBITDA margin of 26%
Net profit increased by 27% to ₹274 crores, while ROCE and ROE stood at 18% and 20% respectively
Added 610 beds in FY26 via new units in Bathinda and Agra; total operational beds reached 3,960 by May 2026
Gross debt drastically reduced from ₹450 crores to ₹28 crores, with plans for full repayment in Q1 FY27
Targeting a total capacity of 5,460 beds by March 2028, supported by ₹329 crores in operating cash flow
👀 What to Watch
Investors should take note of the company's aggressive deleveraging and clear roadmap to increase bed capacity by nearly 50% by 2028. The stock remains a strong growth play in the North Indian healthcare sector given its high capital efficiency and improving ARPOB.
Par Drugs Reports FY26 Results; Board Authorizes ₹90 Crore Investment Limit
Par Drugs and Chemicals Limited reported its audited financial results for the fiscal year ended March 31, 2026, maintaining a debt-free balance sheet. Total equity grew to ₹111.98 crore from ₹98.97 crore in the previous year, while cash and cash equivalents surged to ₹41.84 crore. A key strategic move includes the board's authorization to invest up to ₹90 crore of surplus funds into liquid and arbitrage instruments. The company also reported a significant reduction in trade receivables, indicating improved collection cycles.
Key Highlights
Total Equity increased by 13.1% year-on-year to ₹111.98 crore as of March 31, 2026.
Company remains debt-free with zero long-term and short-term borrowings.
Cash and cash equivalents grew by 51.7% to ₹41.84 crore from ₹27.58 crore.
Board authorized a new investment limit of ₹90 crore for surplus funds in liquid and arbitrage funds.
Trade receivables improved significantly, dropping to ₹12.03 crore from ₹16.71 crore year-on-year.
👀 What to Watch
The company's strong cash position and debt-free status provide a solid margin of safety. Investors should monitor the deployment of the ₹90 crore surplus for potential future expansions or acquisitions.
Par Drugs Reports FY26 Results; Approves ₹90 Cr Investment Limit and Remains Debt-Free
Par Drugs and Chemicals Limited has reported its audited financial results for the fiscal year ended March 31, 2026, showcasing a robust balance sheet. The company's total equity grew to ₹111.98 crore from ₹98.97 crore YoY, while maintaining a debt-free status with zero borrowings. A key highlight is the board's authorization to invest up to ₹90 crore in liquid and arbitrage funds, supported by a significant increase in cash and cash equivalents to ₹41.84 crore. Additionally, trade receivables improved, dropping to ₹12.03 crore from ₹16.71 crore, indicating efficient working capital management.
Key Highlights
Total equity increased by 13.1% YoY to ₹111.98 crore as of March 31, 2026
Cash and cash equivalents surged to ₹41.84 crore from ₹27.58 crore in the previous year
Board approved a significant investment limit of up to ₹90 crore for surplus funds
Company remains debt-free with zero long-term and short-term borrowings
Trade receivables decreased by 28% to ₹12.03 crore, reflecting better collection cycles
👀 What to Watch
The company's debt-free status and substantial cash reserves provide a strong margin of safety. Investors should monitor the deployment of the ₹90 crore investment limit and look for future expansion plans funded by these internal accruals.
Par Drugs FY26 Results: Board OKs ₹90 Cr Investment; SEBI Restrains Restructuring Plan
Par Drugs and Chemicals approved its FY26 audited results with an unmodified auditor's opinion. The board has authorized management to invest surplus funds up to ₹90 crore in liquid and arbitrage instruments, indicating a strong cash position. However, a significant regulatory hurdle has emerged as SEBI issued an order restraining a previously proposed strategic restructuring involving a slump sale to a related party. The company also renewed its ₹1.61 crore banking facility and distributed ₹25.14 lakh in employee bonuses.
Key Highlights
Board authorized investment of surplus funds up to ₹90.00 Crore in liquid funds, arbitrage funds, and FDs.
SEBI issued an Interim/Confirmatory Order restraining a proposed slump sale/business transfer to a related party.
Renewed existing banking facility of ₹161.00 Lakh with Kotak Mahindra Bank without limit revisions.
Distributed 10% employee bonus totaling ₹25.14 Lakh for the financial year 2025-26.
Audited financial results for Q4 and FY26 approved with an unmodified audit opinion.
👀 What to Watch
Investors should closely monitor the legal developments regarding the SEBI order on the business transfer, as it impacts the company's strategic direction. While the ₹90 crore investment limit suggests high liquidity, the regulatory overhang remains a primary concern.
Par Drugs Q4 Results Approved; Board Authorizes ₹90 Cr Investment Amid SEBI Restraint
Par Drugs and Chemicals approved its FY26 audited results with an unmodified auditor's opinion. The board has authorized the management to invest surplus funds up to ₹90 crore in liquid and arbitrage funds, indicating strong liquidity. However, the auditor's report highlights a significant regulatory hurdle as SEBI has restrained the company's proposed strategic restructuring involving a slump sale to a related party. The company also renewed a ₹1.61 crore banking facility and paid a 10% employee bonus totaling ₹25.14 lakh.
Key Highlights
Authorized investment of surplus funds up to ₹90.00 crore in liquid funds, arbitrage funds, and fixed deposits.
SEBI issued an Interim and Confirmatory Order restraining the company's proposed slump sale/business transfer to a related party.
Approved audited financial results for FY ended March 31, 2026, with an unmodified auditor's opinion.
Renewed existing banking facility of ₹161.00 lakh with Kotak Mahindra Bank without revision.
Distributed 10% employee bonus amounting to ₹25.14 lakh for the financial year 2025-26.
👀 What to Watch
Investors should closely monitor the legal developments regarding the SEBI order on the business transfer, as this restructuring was a major strategic move. While the ₹90 crore investment capacity shows financial strength, the regulatory intervention introduces significant uncertainty.
Par Drugs FY26 Results: SEBI Restrains Restructuring Plan; ₹90 Cr Investment Limit Approved
Par Drugs and Chemicals approved its audited financial results for the fiscal year ended March 31, 2026, receiving an unmodified auditor's opinion. However, the auditor highlighted a significant regulatory hurdle: SEBI has issued an interim order restraining a proposed strategic restructuring involving a slump sale to a related party. On the liquidity front, the board has authorized a substantial investment limit of up to ₹90 crore in liquid and arbitrage funds. The company also renewed its ₹1.61 crore banking facility and distributed ₹25.14 lakh in employee bonuses.
Key Highlights
SEBI issued an Ex-Parte Interim Order restraining the company's proposed slump sale of its primary business undertaking.
Board authorized new investment limits up to ₹90.00 Crore in liquid funds, arbitrage funds, and fixed deposits.
Audited financial results for FY 2025-26 approved with an unmodified opinion from statutory auditors.
Renewal of banking facility with Kotak Mahindra Bank maintained at ₹161.00 Lakh.
Paid ₹25.14 lakh as a 10% bonus to employees for the financial year 2025-26.
👀 What to Watch
Investors should exercise caution and monitor developments regarding the SEBI order, as the restraint on restructuring impacts the company's long-term strategy. The large ₹90 crore investment authorization suggests significant cash reserves, but the regulatory uncertainty remains a primary concern.
Parag Milk Foods FY26 Revenue Hits ₹3,800 Cr; New Age Business Grows 91%
Parag Milk Foods reported a strong FY26 with annual revenue crossing ₹3,800 crores and a 5% overall volume growth. The company's New Age business, comprising Avvatar and Pride of Cows, saw a massive 91% growth, now contributing 10% to total revenue. Despite a 15% YoY increase in milk prices to ₹42/litre, Q4 gross margins improved to 28% through better product mix and pricing discipline. Management aims for the New Age segment to reach 20-25% of total revenue within the next 3-5 years.
Key Highlights
Annual revenue crossed ₹3,800 crores with core category volume growth of 8%
New Age business (Avvatar & Pride of Cows) revenue grew 91% YoY, reaching ₹100 crores per quarter
Q4 gross margins expanded to 28% despite average milk prices rising 15% YoY to ₹42 per litre
Avvatar holds a 14-15% market share in the protein segment across quick commerce and marketplaces
Planned cheese capacity expansion from 60 metric tons to 80 metric tons to meet growing demand
👀 What to Watch
Investors should focus on the rapid scaling of the high-margin Avvatar brand and the company's successful premiumization strategy. The transition toward a 25% revenue contribution from the New Age segment suggests a structural improvement in long-term profitability.
